biostudies-literatureHuang CFMinistry of EducationKaohsiung Medical UniversityMinistry of Health and WelfareKaohsiung Medical University Hospital883-894https://www.ebi.ac.uk/biostudies/studies/S-EPMC11540343biostudies-literatureUnknown30(4)<h4>Background/aims</h4>Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.<h4>Methods</h4>We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.<h4>Results</h4>There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) dClinical and molecular hepatologyDynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan.PMC11540343111CM-KMU-07(KMUHDK(A)113002KMUH111-1R02KMUH111-1R05NSTC 112-2314-B-037-087KMUH111-1R06MOHW113-TDU-B-221-124007NSTC 112-2923-B-037-002-MY3KMUH-DK(C)111004NSTC112-2314-B-037-004KMUH112-2R07NSTC 112-2314-B-037-009NYCUKMU-111-I004KMUH-DK(B)111003~2KMUH112-2R11MOST111-2314-B-037-069-MY2NSTC 112-2314-B-037-076-MY3Tsai PCWei YJJang TYHsieh MYHuang CFHuang CKWang CWLin YHLin TCChuang WLYu MLDai CYLiang PCYeh MLHuang JFfalseDynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan.<h4>Background/aims</h4>Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.<h4>Methods</h4>We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.<h4>Results</h4>There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) d2024-01-01T00:00:00Z2024 Oct2025-04-04T02:36:07.159Z2025-04-04T02:36:07.159ZS-EPMC115403433906972110.3350/cmh.2024.0414